Scarica l'app Stockscreener
9.93
1.02%
0.10
Precedente Chiudi:
$9.83
Aprire:
$9.79
Volume 24 ore:
63,658
Relative Volume:
0.61
Capitalizzazione di mercato:
$84.60M
Reddito:
$153.73M
Utile/perdita netta:
$-106.79M
Rapporto P/E:
-5.5787
EPS:
-1.78
Flusso di cassa netto:
$-115.93M
1 W Prestazione:
+16.89%
1M Prestazione:
+9.75%
6M Prestazione:
+24.26%
1 anno Prestazione:
-53.16%
Intervallo 1D:
$9.525
$10.10
Intervallo di 1 settimana:
$8.12
$10.10
Portata 52W:
$5.231
$21.90
Sutro Biopharma Inc Stock (STRO) Company Profile
Nome
Sutro Biopharma Inc
Settore
Industria
Telefono
650-392-8412
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta STRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
9.93 | 83.75M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-05-08 | Iniziato | BofA Securities | Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-06 | Iniziato | Oppenheimer | Outperform |
| 2023-03-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2021-06-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-07-16 | Iniziato | Wells Fargo | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-10-07 | Iniziato | BTIG Research | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-22 | Iniziato | Wedbush | Outperform |
Mostra tutto
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Wells Fargo Reaffirms Their Hold Rating on Sutro Biopharma (STRO) - The Globe and Mail
RBF Capital LLC Purchases New Position in Sutro Biopharma, Inc. $STRO - MarketBeat
Velan Capital Investment Management LP Acquires 2,030,000 Shares of Sutro Biopharma, Inc. $STRO - MarketBeat
Exit Recap: Will Sutro Biopharma Inc stock benefit from automationTrade Analysis Report & Low Risk Growth Stock Ideas - moha.gov.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Shares Gap DownWhat's Next? - MarketBeat
Will Sutro Biopharma Inc. (S09) stock sustain bullish trend into 20252025 Big Picture & AI Forecasted Stock Moves - Newser
Can Sutro Biopharma Inc. stock sustain institutional interestJuly 2025 Institutional & Smart Investment Allocation Tips - Newser
Is Sutro Biopharma Inc. (S09) stock a top dividend aristocrat candidatePrice Action & Weekly Market Pulse Alerts - Newser
Sutro Biopharma (NASDAQ:STRO) Shares Gap UpWhat's Next? - MarketBeat
Is Sutro Biopharma Inc. (S09) stock attractive for growth fundsPortfolio Risk Report & Weekly Watchlist of Top Performers - Newser
Sutro Biopharma doses first patients in phase 1 trial of STRO-004 - Investing.com Canada
Sutro Biopharma (NASDAQ:STRO) Receives "Neutral" Rating from Wedbush - MarketBeat
Sutro Biopharma Announces Reverse Stock Split - TipRanks
Sutro Biopharma (NASDAQ:STRO) Given Neutral Rating at Wedbush - Defense World
Sutro Biopharma Initiates Dosing in Phase 1 TF-Expressing Cancer Study - MarketScreener
Sutro Biopharma (STRO) Initiates Phase 1 Trial of STRO-004 for S - GuruFocus
Sutro Biopharma announces first cohort of patients dosed in phase 1 trial of Stro-004 - marketscreener.com
Are Smart Investors Making the Right Decision? Sutro Biopharma Inc (STRO) - setenews.com
Sutro Biopharma doses first patients in phase 1 trial of STRO-004 By Investing.com - Investing.com South Africa
Sutro Biopharma, Inc. Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in Tissue Factor - marketscreener.com
What MACD trends signal for Sutro Biopharma Inc. (S09) stockWeekly Market Outlook & Low Volatility Stock Recommendations - Newser
Will Sutro Biopharma Inc. stock outperform value stocks2025 Market Overview & AI Enhanced Execution Alerts - Newser
Sutro Biopharma falls as it announces 1-for-10 reverse stock split - MSN
Why Sutro Biopharma Inc. stock is popular among millennials2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - Newser
How Sutro Biopharma Inc. stock reacts to inflationary pressures2025 Big Picture & High Return Trade Opportunity Guides - Newser
What earnings margins imply for Sutro Biopharma Inc. (S09) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Sutro Biopharma announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Sutro Biopharma stock falls after announcing 1-for-10 reverse split - Investing.com Canada
Sutro Biopharma Sets 1-for-10 Reverse Stock Split - Nasdaq
Sutro Biopharma Announces 1-for-10 Reverse Stock Split - The Manila Times
Sutro Biopharma announces 1-for-10 reverse stock split - marketscreener.com
Can Sutro Biopharma Inc. stock continue upward trendMarket Risk Analysis & Reliable Price Breakout Alerts - BỘ NỘI VỤ
Holdings of Sutro Biopharma Inc (STRO) are aligned with the stars - Setenews
Is Sutro Biopharma Inc. stock a contrarian buyQuarterly Investment Review & Risk Managed Trade Strategies - moha.gov.vn
Can Sutro Biopharma Inc. stock reach $100 price target2025 Top Decliners & Daily Profit Focused Screening - newser.com
How reliable is Sutro Biopharma Inc. (S09) stock dividend growthMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
Why Sutro Biopharma Inc. stock attracts global investorsSwing Trade & High Conviction Investment Ideas - newser.com
Statistical indicators supporting Sutro Biopharma Inc.’s strengthWeekly Investment Summary & Consistent Income Trade Ideas - newser.com
Can Sutro Biopharma Inc. recover in the next quarterPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Applying big data sentiment scoring on Sutro Biopharma Inc.2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Can Sutro Biopharma Inc. (S09) stock sustain institutional flowsWeekly Profit Recap & Verified Technical Trade Signals - newser.com
Sutro Biopharma Inc Azioni (STRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sutro Biopharma Inc Azioni (STRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chow Gregory K. | CFO |
Oct 15 '25 |
Buy |
0.81 |
19,750 |
15,998 |
19,750 |
| Chung Jane | Chief Executive Officer |
Oct 15 '25 |
Buy |
0.80 |
12,500 |
10,011 |
122,850 |
| MATSUI CONNIE | Director |
Oct 15 '25 |
Buy |
0.80 |
50,000 |
39,950 |
50,000 |
| Pauling David | Chief Admin. Ofcr. & GC |
Oct 15 '25 |
Buy |
0.80 |
12,504 |
9,993 |
71,737 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
68,249 |
| Leyman Barbara | Chief Business Officer |
Jul 08 '25 |
Option Exercise |
0.00 |
25,000 |
0 |
25,000 |
| Chung Jane | Chief Executive Officer |
Aug 09 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
117,058 |
| ALBINI EDWARD C | CFO AND SECRETARY |
May 15 '25 |
Option Exercise |
0.00 |
44,719 |
0 |
176,800 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):